2 results
Approved WMOCompleted
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
Approved WMOCompleted
Primary Trial Objective:To assess the effect of reversal of neuromuscular blockade with sugammadex 4 mg.kg-1 compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of adjudicated postsurgical events of…